BOT has to pay substantial royalities (license payments) to their licensor. They will look to make a one-off payment to the licensor in order to reduce these royalties. It will be cheaper (but riskier) to do it now, as there is no FDA approval / USA revenue. It ultimately means they can keep more of the income from sales.
BOT has to pay substantial royalities (license payments) to...
-
- There are more pages in this discussion • 186 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $678.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 36.3¢ | $1.835M | 4.963M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13513 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 25681 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |